Hongtao Li, Xiangdi Zhao, Jing Xie, Xingyu Zhu, Yue Su, Cuixia He, Jiaxiang Ding, Minhui Zhu, Yuanyuan Xu, Ying Wang, Rongfang Shan, Bingyan Liu, Yuzhou Ding, Yuanyuan Liu, Huan Zhou, Yunqiu Xie
BACKGROUND: The biosimilar landscape for malignancies continues to grow, with several biosimilars for reference product bevacizumab currently available. Bevacizumab has been shown to be well tolerated; however, the safety of recombinant humanized anti-vascular endothelial growth factor (VEGF) monoclonal antibody injection remains unclear. This study aimed to compare the pharmacokinetics (PK), safety, and immunogenicity of recombinant humanized anti-VEGF monoclonal antibody injection to that of Avastin® in healthy Chinese male volunteers...
May 27, 2023: BMC Pharmacology & Toxicology